---
title: "Novo Beat Eli Lilly Head-to-Head in weight loss drug showdown"
description: "CagriSema cut body weight 12.4% to tirzepatide's 9.1% in a direct phase 3 head-to-head, and Novo's stock fell anyway. The FDA rules on the drug in Q4, with Medicare already paying for the rivals and Lilly $6.5 billion deep in new pill capacity."
publisher: "The Inference"
section: "Health"
published: 2026-09-26T01:48:51.254Z
modified: 2026-09-26T01:48:51.254Z
canonical: https://theinference.org/article/novo-beat-tirzepatide-head-to-head-against-a-third-of-lilly-s-top-dose
language: en
keywords: "Novo Nordisk, Eli Lilly, GLP-1, Medicare, Pharma"
---

# Novo Beat Eli Lilly Head-to-Head in weight loss drug showdown

> CagriSema cut body weight 12.4% to tirzepatide's 9.1% in a direct phase 3 head-to-head, and Novo's stock fell anyway. The FDA rules on the drug in Q4, with Medicare already paying for the rivals and Lilly $6.5 billion deep in new pill capacity.

[Novo](https://theinference.org/markets/companies/novo-nordisk) has spent the tirzepatide era as the smaller player: 39% of the obesity drug market to [Lilly](https://theinference.org/markets/companies/eli-lilly)'s 60% as of the first quarter [7]. At its Capital Markets Day in London on 21 September 2026, Novo announced the answer it has been building.

*Chart: **Lilly's revenue roughly doubled in the tirzepatide era while Novo's stalled** Column chart of Eli Lilly and Novo Nordisk quarterly revenue across eight quarters, Q3 2024 to Q2 2026: Lilly climbs from $11.4B to $23.0B while Novo stays between $10.5B and $14.9B.*

*Company-wide quarterly revenue in US dollars, from each company's SEC filings, rounded to $0.1B. Lilly grew from $11.4B in Q3 2024 to $23.0B in Q2 2026 while Novo went from $10.5B to $12.0B. Sources: Sharadar quarterly fundamentals, retrieved 24 September 2026. [11][12]*

[In REIMAGINE 5, a phase 3 trial putting once-weekly CagriSema 1.0/1.0 mg directly against tirzepatide 5 mg](https://www.globenewswire.com/news-release/2026/09/21/3365319/0/en/novo-s-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-in-reimagine-5-trial.html) in adults with type 2 diabetes, CagriSema patients lost an estimated 12.4% of body weight at week 60 against 9.1% for tirzepatide, with non-inferior HbA1c reduction, 1.71% to 1.67% [1][2][3]. In REDEFINE 9, in obesity, CagriSema delivered 21.0% weight loss against 2.0% for placebo [2].

*Chart: **CagriSema beat tirzepatide head-to-head and hit 21% against placebo** Bar chart of average weight loss by trial arm: CagriSema 21% in obesity (REDEFINE 9), CagriSema 12.4% and tirzepatide 5 mg 9.1% in type 2 diabetes (REIMAGINE 5), and placebo 2%.*

*Estimated average change in body weight by trial arm, percent. REIMAGINE 5 measured week 60 in adults with type 2 diabetes; REDEFINE 9 measured week 68 in adults with overweight or obesity; all figures based on the efficacy estimand. Sources: Novo Nordisk release, 21 September 2026; MPR, 21 September 2026. [1][2][3]*

## The stock fell anyway

The win did not lift the shares. They fell as much as 9% on Monday as analysts pressed Novo on pricing power and dealmaking ahead of semaglutide patent expiries in the early 2030s [4], extending a year-to-date decline of 21% [5]. The fall suggests the market was trading the 2035 target of DKK 150 billion in pipeline sales, about $23 billion, and a CagriSema launch planned for early next year [4], not Monday's numbers.

![Novo Nordisk chief executive Mike Doustdar speaking on stage](https://storage.googleapis.com/theinference-public/img/0b747e1ce9aac1aa.jpg)

*Novo Nordisk chief executive Mike Doustdar. His Capital Markets Day in London paired the CagriSema head-to-head win with 2035 targets the market did not buy. (Canyak1982)*

## The comparator was 5 mg, not Lilly's ceiling

The fight inside the data is the dose. REIMAGINE 5 ran tirzepatide at 5 mg; [the approved Zepbound and Mounjaro label climbs in 2.5 mg steps to a 15 mg maximum](https://www.forbes.com/health/weight-loss/cagrisema-vs-tirzepatide/) [6]. Novo's release anticipates the objection, arguing treatment is individualised and "not all patients receive or remain on the highest available dose" [2].

Every headline figure also rests on the efficacy estimand, per the release's footnote [2]. Lilly's strongest dose never entered the ring.

## Medicare is paying while Lilly builds

Since 1 July 2026, [Medicare's Bridge program](https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html) has sold obesity GLP-1s to seniors at $50 a month through 2027: Wegovy's pill and injection, Zepbound's KwikPen and Lilly's Foundayo [7]. KFF counts 3.8 million eligible seniors, and a Medicare bill of $1.3 billion to $3.3 billion if 10% to 25% of them participate [8].

CagriSema reaches that list only if the FDA approves the December 2025 weight-management filing, a decision due in Q4 [2]. The day Novo read out, [Lilly broke ground on a $6.5 billion Houston plant to make Foundayo](https://finance.yahoo.com/healthcare/articles/eli-lilly-company-breaks-ground-215518225.html) [9][10], a bet The Inference framed as [a hedge on a pill shift Novo dominates](https://theinference.org/article/lilly-breaks-ground-on-6-5-billion-to-supply-the-pill-boom-medicare-is-funding).

## The Q4 verdict is the tell

Watch the FDA decision, then the formularies. If an approved CagriSema lands on public money at a ranked price, Lilly has just poured $6.5 billion into capacity for a race it can now lose on data.

## Takeaway

CagriSema beat tirzepatide 12.4% to 9.1% against a third of Lilly's top dose, but Novo's Q4 FDA decision decides whether the win reaches Medicare money and Lilly's new $6.5 billion pill capacity.

## Sources

1. [Investegate, "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial," 21 September 2026](https://www.investegate.co.uk/announcement/gnw/novo-nordisk-a-s-class-b--0qiu/novo-s-cagrisema-delivers-superior-weight-los-/9782248)
2. [Novo Nordisk via GlobeNewswire, "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial," 21 September 2026](https://www.globenewswire.com/news-release/2026/09/21/3365319/0/en/novo-s-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-in-reimagine-5-trial.html)
3. [MPR, "Phase 3 Data Show CagriSema Drives Significant Weight Loss," 21 September 2026](https://www.empr.com/news/cagrisema-superior-weight-loss-tirzepatide-reimagine5/)
4. [Reuters (Wingrove and Rasmussen) via MSN, "Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says," 21 September 2026](https://www.msn.com/en-us/news/other/novo-nordisk-aims-to-launch-more-than-five-blockbuster-drugs-by-2030-ceo-says/ar-AA2cFxc4)
5. [Ad Hoc News, "Novo Nordisk's CagriSema Beats Tirzepatid in Head-to-Head Trial, Yet Shares Slide as London Strategy Day Disappoints," 22 September 2026](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/novo-nordisk-s-cagrisema-beats-tirzepatid-in-head-to-head-trial-yet/70149786)
6. [Forbes Health, "CagriSema vs. Tirzepatide For Weight Loss: What's the Difference?," 30 June 2026](https://www.forbes.com/health/weight-loss/cagrisema-vs-tirzepatide/)
7. [CNBC, "Medicare will start covering obesity drugs for the first time. Here's what patients should know," 30 June 2026](https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html)
8. [TechTarget Healthcare Payers, "3.8M qualify for Medicare GLP-1 Bridge at program's July start," 1 July 2026](https://www.techtarget.com/healthcarepayers/news/366645372/38M-qualify-for-Medicare-GLP-1-Bridge-at-programs-July-start)
9. [MT Newswires via Yahoo Finance, "Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site," 21 September 2026](https://finance.yahoo.com/healthcare/articles/eli-lilly-company-breaks-ground-215518225.html)
10. [Simply Wall St via Yahoo Finance, "Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?," 22 September 2026](https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-investors-watch-211523509.html)
11. [Sharadar quarterly fundamentals, from Eli Lilly's SEC filings, retrieved 24 September 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478)
12. [Sharadar quarterly fundamentals, from Novo Nordisk's SEC filings, retrieved 24 September 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278)


---

Novo Beat Eli Lilly Head-to-Head in weight loss drug showdown — The Inference. Canonical: https://theinference.org/article/novo-beat-tirzepatide-head-to-head-against-a-third-of-lilly-s-top-dose
